3 results
The primary objective of this study is to investigate if single-inhaler triple therapy (SITT, in this study Trimbow®) is superior to multi-inhaler triple therapy (MITT, in this study Bevespi® and Qvar®) in terms of adherence to inhaled…
Primary objective:• To assess, in healthy subjects, the pharmacodynamic (PD) properties of PCC in the presence and absence of selected DOACs.Secondary objectives:• To assess, in healthy subjects, the safety and tolerability of PCC in the presence…
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.